Effects of the immunosuppressant methotrexate in ponies.
D000818:Animals; D001593:Benzyl Compounds / Q000008:administration & dosage; D001831:Body Temperature; D001835:Body Weight; D004809:Ephedrine / Q000008:administration & dosage / Q000494:pharmacology; D004906:Erythrocyte Count; D005029:Ethylenediamines / Q000008:administration & dosage / Q000494:pharmacology; D005767:Gastrointestinal Diseases / Q000662:veterinary; D006400:Hematocrit; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006734:Horse Diseases / Q000139:chemically induced / Q000473:pathology; D006736:Horses / Q000276:immunology*; D007165:Immunosuppression Therapy; D007273:Injections, Intramuscular; D007958:Leukocyte Count; D008727:Methotrexate / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D011725:Pyridines / Q000008:administration & dosage; D013319:Strongyle Infections, Equine / Q000209:etiology / Q000276:immunology / Q000473:pathology
D001593:Benzyl Compounds; D005029:Ethylenediamines; D006634:Histamine H1 Antagonists; D011725:Pyridines; D004809:Ephedrine; D008727:Methotrexate